COSTS, EFFECTS AND C/E-RATIOS ALONGSIDE A CLINICAL-TRIAL
COSTS, EFFECTS AND C/E-RATIOS ALONGSIDE A CLINICAL-TRIAL
复制标题
DOI：
10.1002/hec.4730030505
复制
发表时间：
1994-09-01
期刊：
影响因子：
2.1
通讯作者：
RUTEN, FFH
中科院分区：
文献类型：
--
作者：
VANHOUT, BA;AL, MJ;RUTEN, FFH
一个一般的方法进行了讨论，以评估周围的成本效益比（C/E比）的基础上，从随机临床试验的数据估计的不确定性。 该方法包括95%概率椭圆的计算，并引入了所谓的C/E-可接受性曲线的概念。 最后一条曲线定义了每个预定义C/E比在研究中发现的C/E比可接受的概率。 该方法是通过估计每个生命挽救的成本和每个病人出院活着的基础上，从一个II期临床试验的数据，解决阿那白滞素治疗脓毒症综合征的价值。
A general approach is discussed to assess the uncertainty surrounding the cost effectiveness ratio (C/E-ratio) estimated on the basis of data from a randomised clinical trial. The approach includes the calculation of a 95% probability ellipse and introduces the concept of a so called C/E-acceptability curve. This last curve defines for each predefined C/E-ratio the probability that the C/E-ratio found in the study is acceptable. The approach is illustrated by estimates of costs per life saved and costs per patient discharged alive on the basis of data from a phase II trial addressing the value of anakinra in treating sepsis syndrome.